We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

7 hedge funds and large institutions have $845K invested in Alexion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 693 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

99% less funds holding

Funds holding: 707 → 7 (-700)

100% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 693

100% less funds holding in top 10

Funds holding in top 10: 77 → 0 (-77)

100% less capital invested

Capital invested by funds: $38.8B → $845K (-$38.8B)

Holders
7
Holders Change
-700
Holders Change %
-99.01%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
-77
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
693
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NICM
Neo Ivy Capital Management
New York
+$475K
2
TAIM
TD Ameritrade Investment Management
Nebraska
+$131K
3
RG
Retirement Group
California
+$9.37K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$3.74B
2
BlackRock
BlackRock
New York
-$3.21B
3
State Street
State Street
Massachusetts
-$1.84B
4
FCM
Farallon Capital Management
California
-$1.42B
5
HI
HBK Investments
Texas
-$1.21B
Name Holding Trade Value Shares
Change 		Change in
Stake
PI
326
Putnam Investments
Massachusetts
– -$2.77M -15,080 Closed
TIAM
327
TT International Asset Management
United Kingdom
– -$2.76M -15,049 Closed
AFM
328
Anson Funds Management
Texas
– -$2.76M -15,000 Closed
TCM
329
Tributary Capital Management
Nebraska
– -$2.76M -15,000 Closed
NMERB
330
New Mexico Educational Retirement Board
New Mexico
– -$2.69M -14,650 Closed
Cambridge Investment Research Advisors
331
Cambridge Investment Research Advisors
Iowa
– -$2.68M -14,573 Closed
APF
332
Alaska Permanent Fund
Alaska
– -$2.65M -14,400 Closed
BG
333
Bellevue Group
Switzerland
– -$2.63M -14,300 Closed
BPC
334
Banque Pictet & Cie
Switzerland
– -$2.59M -14,090 Closed
PTC
335
Private Trust Company
Ohio
– -$2.57M -13,996 Closed
SMDAM
336
Sumitomo Mitsui DS Asset Management
Japan
– -$2.54M -13,841 Closed
UIM
337
USS Investment Management
United Kingdom
– -$2.54M -13,800 Closed
Two Sigma Advisers
338
Two Sigma Advisers
New York
– -$2.52M -13,700 Closed
AW
339
ACG Wealth
Georgia
– -$2.48M -13,498 Closed
CL
340
CSS LLC
Illinois
– -$2.47M -13,445 Closed
Rockefeller Capital Management
341
Rockefeller Capital Management
New York
– -$2.43M -13,253 Closed
EI
342
EDMP Inc
Florida
– -$2.44M -13,252 Closed
TI
343
Telemetry Investments
New York
– -$2.39M -13,000 Closed
Mackenzie Financial
344
Mackenzie Financial
Ontario, Canada
– -$2.37M -12,876 Closed
KRS
345
Kentucky Retirement Systems
Kentucky
– -$2.36M -12,870 Closed
PAMG
346
Patton Albertson Miller Group
Tennessee
– -$2.28M -12,411 Closed
FMWA
347
Forvis Mazars Wealth Advisors
Missouri
– -$2.27M -12,329 Closed
X
348
Xponance
Pennsylvania
– -$2.24M -12,207 Closed
IMRF
349
Illinois Municipal Retirement Fund
Illinois
– -$2.17M -11,806 Closed
LS
350
Livforsakringsbolaget Skandia
Sweden
– -$2.16M -11,772 Closed
12 13
14
15 16

ALXN Hedge Fund Activity: Q3 2021 in Review

7 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2021, worth a combined $845K — down 100% from $38.8B a quarter earlier.

Sellers outnumbered buyers: 693 funds closed out of ALXN and 1 opened new positions — a net loss of 692 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Neo Ivy Capital Management, opening a new position worth an estimated $475K. The largest seller was Vanguard Group, exiting entirely with an estimated $3.74B sold.

  • 7 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2021, down from 707 in Q2 2021.
  • Funds reported $845K of Alexion Pharmaceuticals stock for Q3 2021, down 100% quarter-over-quarter.
  • 1 fund opened new Alexion Pharmaceuticals positions in Q3 2021 and 693 closed out, a net change of -692 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2021 was Neo Ivy Capital Management, an estimated $475K added.
  • The largest Alexion Pharmaceuticals seller in Q3 2021 was Vanguard Group, an estimated $3.74B sold.

Based on aggregated 13F filings for Q3 2021.